<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590300</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00980-39</org_study_id>
    <nct_id>NCT04590300</nct_id>
  </id_info>
  <brief_title>Impact of Cognitive &amp; Metacognitive Performance on Knowledge Learning When Conducting Therapeutic Education Programs</brief_title>
  <acronym>MetaCOGNITION</acronym>
  <official_title>Impact Des Performances Cognitives et métacognitives Sur l'Apprentissage de Connaissances Lors de la réalisation de Programmes d'éducation thérapeutique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Charles Perrens, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Charles Perrens, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with schizophrenia and bipolar disorder display alterations in cognition and&#xD;
      metacognition. These alterations may have an impact on learning during therapeutic education&#xD;
      programs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Therapeutic Education (FTE) is defined as a practice to help patients to acquire or&#xD;
      maintain the skills needed to best manage their lives with a chronic disease. FTE includes&#xD;
      organized awareness, information, learning and psychological and social assistance about the&#xD;
      disease, prescribed treatments, various treatments offered, as well as information on&#xD;
      organization of the global health system, and health behaviours. Performed by health&#xD;
      professionals trained in this practice, FTE is intended to help patients and their close&#xD;
      relatives and to understand their pathology, their treatments, collaborate with health care&#xD;
      teams, and maintain or improve their quality of life. It aims to produce a complementary&#xD;
      therapeutic effect of other health care interventions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of cognitive impairments on knowledge acquired through a therapeutic education program with Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>1 year</time_frame>
    <description>assess the impact of possible cognitive impairments on knowledge acquired through a therapeutic education program Minimum value = 0 &amp; Maximum value = 30 Score &lt; 26 is considered as abnormal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of metacognitive impairments on knowledge acquired through a therapeutic education program with Subjective Scale To Investigate Cognition in Schizophrenia (SSTICS)</measure>
    <time_frame>1 year</time_frame>
    <description>assess the impact of possible metacognitive impairments on knowledge acquired through a therapeutic education program Minimum value 21</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assess the impact of self esteem acquired through a therapeutic education program with Rosenberg scale</measure>
    <time_frame>1 year</time_frame>
    <description>assess the evolution in self-esteem following this program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the impact of level of anxiety, acquired through a therapeutic education program with State-Trait-Anxiety Inventory (Forme Y) (STAI-Y) questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>assess the evolution in level of anxiety following this program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the impact of depressive symptomatology acquired through a therapeutic education program with Center for Epidemiologic Studies-Depression (CES-D) scale</measure>
    <time_frame>1 year</time_frame>
    <description>assess the evolution in depressive symptoms following this program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the impact of literacy on knowledge acquired through a therapeutic education program with Rapid Estimate for Adult Literacy in Medicine (REALM-R) questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>assess the evolution in quality of life following this program.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Schizophrenia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 questionnaire at the beginning of the study, before FTE program&#xD;
1 questionnaire at the end of FTE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar disorder</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 questionnaire at the beginning of the study, before FTE program&#xD;
1 questionnaire at the end of FTE</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QUESTIONNAIRES</intervention_name>
    <description>1 questionnaire at the beginning of the study, before FTE program&#xD;
1 questionnaire at the end of FTE</description>
    <arm_group_label>Bipolar disorder</arm_group_label>
    <arm_group_label>Schizophrenia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consent to participate in the study,&#xD;
&#xD;
          -  Suffering from a chronic condition for which an therapeutic patient education (TEP)&#xD;
             program is proposed.&#xD;
&#xD;
          -  Mastering the French language.&#xD;
&#xD;
          -  Be a beneficiary of health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor understanding of instructions that make it impossible to consent or assess&#xD;
&#xD;
          -  Neurodegenerative disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clelia QUILES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Charles Perrens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clelia QUILES, MD</last_name>
    <phone>+335 56 56 35 85</phone>
    <email>cquiles@ch-perrens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helen SAVARIEAU</last_name>
    <phone>+33556563556</phone>
    <email>hsavarieau@ch-perrens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier CHARLES PERRENS</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clélia QUILES, MD</last_name>
      <phone>+33556563585</phone>
      <email>cquiles@ch-perrens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Helen SAVARIEAU</last_name>
      <phone>+33556563556</phone>
      <email>hsavarieau@ch-perrens.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Clélia QUILES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD002831. doi: 10.1002/14651858.CD002831.pub2. Review.</citation>
    <PMID>21678337</PMID>
  </reference>
  <reference>
    <citation>Soo SA, Zhang ZW, Khong SJ, Low JEW, Thambyrajah VS, Alhabsyi SHBT, Chew QH, Sum MY, Sengupta S, Vieta E, McIntyre RS, Sim K. Randomized Controlled Trials of Psychoeducation Modalities in the Management of Bipolar Disorder: A Systematic Review. J Clin Psychiatry. 2018 May/Jun;79(3). pii: 17r11750. doi: 10.4088/JCP.17r11750.</citation>
    <PMID>29727072</PMID>
  </reference>
  <reference>
    <citation>Flavell J.H. Metacognition and cognitive monitoring. A new area of cognitive-developmental inquiry. Am Psychol. 1979; 34(10):906-11</citation>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

